ACS Medicinal Chemistry Letters
Letter
(19) Wang, P. A.; Xian, M.; Tang, X.; Wu, X.; Wen, Z.; Cai, T.; Janczuk,
A. J. Nitric Oxide Donors: Chemical Activities and Biological
Applications. Chem. Rev. 2002, 102, 1091−1134.
ABBREVIATIONS
■
PDN, painful diabetic neuropathy; NO, nitric oxide; PRG150, 3-
methyl-4-furoxancarbaldehyde; PET, positron emission tomog-
raphy; μPET, micropositron emission tomography; CT,
computed tomography; Pd2(dba)3, tris(dibenzylideneacetone)
dipalladium (0); ROI, region of interest; SC, subcutaneous; IV,
intravenous; SUV, standard uptake value; QMA, quaternary
methylammonium; NADPH, nicotinamide adenine dinucleotide
phosphate
́
(20) Pasinszki, T.; Havasi, B.; Hajgato, B.; Westwood, N. P. C.
Synthesis, Spectroscopy and Structure of the Parent Furoxan (HCNO)
2. J. Phys. Chem. A 2009, 113, 170−176.
(21) Medana, C.; Ermondi, G.; Fruttero, R. Furoxans as Nitric Oxide
Donors. 4-Phenyl-3-Furoxancarbonitrile: Thiol-Mediated Nitric Oxide
Release and Biological Evaluation. J. Med. Chem. 1994, 37, 4412−4416.
(22) Ferioli, R.; Folco, G. C.; Ferretti, C.; Gasco, A. M.; Medana, C.;
Fruttero, R.; Civelli, M.; Gasco, A. A New Class of Furoxan Derivatives
as NO Donors: Mechanism of Action and Biological Activity. Br. J.
Pharmacol. 1995, 114, 816−820.
REFERENCES
■
(23) Di Stilo, A.; Cena, C.; Gasco, A. M.; Gasco, A.; Ghigo, D.
Glutathione Potentiates cGNP Synthesis Induced by the Two
Phenylfuroxancarbonitrile Isomers in RFL-6 Cells. Bioorg. Med. Chem.
Lett. 1996, 6, 2607−2612.
(24) Sako, M.; Oda, S.; Ohara, S.; Hirota, K.; Maki, Y. Facile Synthesis
and NO-Generating Property of 4H-[1,2,5]Oxadiazolo[3,4-D]-
Pyrimidine-5,7-Dione 1-Oxides. J. Org. Chem. 1998, 63, 6947−6951.
(25) Nirode, W. F.; Luis, J. M.; Wicker, J. F.; Wachter, N. M. Synthesis
and Evaluation of NO-Release From Symmetrically Substituted
Furoxans. Bioorg. Med. Chem. Lett. 2006, 16, 2299−2301.
(26) Sorba, G.; Medana, C.; Fruttero, R.; Cena, C.; Di Stilo, A.; Galli,
U.; Gasco, A. Water Soluble Furoxan Derivatives as NO Prodrugs. J.
Med. Chem. 1997, 40, 463−469.
(27) Huang, L. Y.; Tsui, D. Y.; Williams, C. M.; Wyse, B. D.; Smith, M.
T. The Furoxan Nitric Oxide Donor, PRG150, Evokes Dose-Dependent
Analgesia in a Rat Model of Painful Diabetic Neuropathy. Clin. Exp.
Pharmacol. Physiol. 2015, 42, 921−929.
(28) Smith, M. T. Pain-Relieving Compositions and Uses Therefor.
Google Patents US 2015/0051404 A1, 2015.
(1) Esplugues, J. V. NO as a Signaling Molecule in the Nervous System.
Br. J. Pharmacol. 2002, 135, 1079−1095.
(2) Hou, Y. C.; Janczuk, A.; Wang, P. G. Current Trends in the
Development of Nitric Oxide Donors. Curr. Pharm. Des. 1999, 5, 417−
441.
(3) Thomas, D. D.; Liu, X.; Kantrow, S. P.; Lancaster, J. R. The
Biological Lifetime of Nitric Oxide: Implications for the Perivascular
Dynamics of NO and O2. Proc. Natl. Acad. Sci. U. S. A. 2001, 98, 355−
360.
(4) Ischiropoulos, H. Biological Tyrosine Nitration: A Pathophysio-
logical Function of Nitric Oxide and Reactive Oxygen Species. Arch.
Biochem. Biophys. 1998, 356, 1−11.
(5) Godecke, A.; Schrader, J.; Reinartz, M. Nitric Oxide-Mediated
̈
Protein Modification in Cardiovascular Physiology and Pathology.
Proteomics: Clin. Appl. 2008, 2, 811−822.
(6) Jin, R. C.; Loscalzo, J. Vascular Nitric Oxide: Formation and
Function. J. Blood Med. 2010, 147−162.
(7) Stamler, J. S.; Meissner, G. Physiology of Nitric Oxide in Skeletal
Muscle. Physiol. Rev. 2001, 81, 209−237.
(29) Ametamey, S. M.; Honer, M.; Schubiger, P. A. Molecular Imaging
with PET. Chem. Rev. 2008, 108, 1501−1516.
(8) Cury, Y.; Picolo, G.; Gutierrez, V. P.; Ferreira, S. H. Pain and
Analgesia: The Dual Effect of Nitric Oxide in the Nociceptive System.
Nitric Oxide 2011, 25, 243−254.
(30) Miller, P. W.; Long, N. J.; Vilar, R.; Gee, A. D. Synthesis of 11C,
18F, 15O, and 13N Radiolabels for Positron Emission Tomography.
Angew. Chem., Int. Ed. 2008, 47, 8998−9033.
(9) Hirst, D.; Robson, T. Targeting Nitric Oxide for Cancer Therapy. J.
Pharm. Pharmacol. 2007, 59, 3−13.
́
(31) Gomez-Vallejo, V.; Gaja, V.; Gona, K. B.; Llop, J. Nitrogen-13:
(10) Wallace, J. L. Nitric Oxide as a Regulator of Inflammatory
Processes. Mem. Inst. Oswaldo Cruz. 2005, 100, 5−9.
Historical Review and Future Perspectives. J. Labelled Compd.
Radiopharm. 2014, 57, 244−254.
(11) Boiani, M.; Cerecetto, H.; Gonzal
Piro, O. E.; Castellano, E. E.; Lopez de Cerai
́
ez, M.; Risso, M.; Olea-Azar, C.;
n, A.; Ezpeleta, O.; Monge-
(32) Fruttero, R.; Ferrarotti, B.; Serafino, A.; Di Stilo, A.; Gasco, A.
Unsymmetrically Substituted Furoxans. Part 11. Methylfuroxancarbal-
dehydes. J. Heterocycl. Chem. 1989, 26, 1345−1347.
́
́
Vega, A. 1,2,5-Oxadiazole N-Oxide Derivatives as Potential Anti-Cancer
Agents: Synthesis and Biological Evaluation. Part IV. Eur. J. Med. Chem.
2001, 36, 771−782.
(33) Thabano, J. R. E.; Abong’o, D.; Sawula, G. M. Determination of
Nitrate by Suppressed Ion Chromatography After Copperised-
Cadmium Column Reduction. J. Chromatogr. A 2004, 1045, 153−159.
́
(12) Cerecetto, H.; Gonzalez, M. Benzofuroxan and Furoxan.
Chemistry and Biology. Top. Heterocycl. Chem. 2007, 10, 265−308.
(13) Balbo, S.; Lazzarato, L.; Di stilo, A.; Fruttero, R.; Lombaert, N.;
Kirsch-Volders, M. Studies of the Potential Genotoxic Effects of
Furoxans: the Case of CAS 1609 and of the Water-Soluble Analogue of
CHF 2363. Toxicol. Lett. 2008, 178, 44−51.
́
(34) Llop, J.; Gomez-Vallejo, V.; Bosque, M.; Quincoces, G.; Penuelas,
̃
I. Synthesis of S-[13N]nitrosoglutathione (13N-GSNO) as a New
Potential PET Imaging Agent. Appl. Radiat. Isot. 2009, 67, 95−99.
́
(35) Gomez-Vallejo, V.; Kato, K.; Oliden, I.; Calvo, J.; Baz, Z.; Borrell,
J. I.; Llop, J. Fully Automated Synthesis of 13N-Labeled Nitrosothiols.
Tetrahedron Lett. 2010, 51, 2990−2993.
(36) Toure, B. B.; Hoveyda, H. R.; Tailor, J.; Ulaczyk-Lesanko, A.; Hall,
́
D. G. A Three-component Reaction for Diversity-Oriented Synthesis of
Polysubstituted Piperidines: Solution and Solid-Phase Optimization of
the First Tandem Aza[4 + 2]/Allyboration. Chem. - Eur. J. 2003, 9, 466−
474.
(37) Schaible, H. Pain Control; Springer, 2015.
(38) Tsukahara, H.; Kaneko, K. Studies on Pediatric Disorders; Springer,
2014.
(14) Bertinaria, M.; Stilo, A. D.; Tosco, P.; Sorba, G.; Poli, E.; Pozzoli,
C.; Coruzzi, G.; Fruttero, R.; Gasco, A. [3-(1H-Imidazol-4-Yl)Propyl]-
Guanidines Containing Furoxan Moieties. Bioorg. Med. Chem. 2003, 11,
1197−1205.
(15) Severina, I. S.; Axenova, L. N.; Veselovsky, A. V.; Pyatakova, N. V.;
Buneeva, O. A.; Ivanov, A. S.; Medvedev, A. E. Nonselective Inhibition
of Monoamine Oxidases A and B by Activators of Soluble Guanylate
Cyclase. Biochemistry (Moscow) 2003, 68, 1048−1054.
(16) Gasco, A.; Fruttero, R.; Sorba, G.; Di Stilo, A.; Calvino, R. NO
Donors: Focus on Furoxan Derivatives. Pure Appl. Chem. 2004, 76,
973−981.
(39) Mahmoud, M. A.; Fahmy, G. H.; Moftah, M. Z.; Sabry, I.
Distribution of Nitric Oxide-Producing Cells Along Spinal Cord in
Urodeles. Front. Cell. Neurosci. 2014, 8, 1−7.
(17) Aguirre, G.; Boiani, M.; Cerecetto, H.; Fernan
́ ́
dez, M.; Gonzalez,
M.; Leon, E.; Pintos, C.; Raymondo, S.; Arredondo, C.; Pacheco, J. P.
́
Furoxan Derivatives as Cytotoxic Agents: Preliminary in vivo
Antitumoral Activity Studies. Pharmazie 2006, 61, 54−59.
(18) Bohn, H.; Brendel, J.; Martorana, P. A.; Schonafinger, K.;
̈
Lombaert, N. Cardiovascular Action of the Furoxan CAS 1609, A Novel
Nitric Oxide Donor. Br. J. Pharmocol. 1995, 114, 1605−1612.
E
ACS Med. Chem. Lett. XXXX, XXX, XXX−XXX